Fidelity Management & Research Co.. recently announced the acquisition of new stake in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). The institutional investor has increased its shareholding in the Healthcare company by 46.60% to 11.86 million shares with purchase of 3.77 million shares. This fresh investment now brings its stake to 10.72% valued currently at $7.5 billion. In addition, The Vanguard Group, Inc. raised its holdings by 1.32 million to 7.35 million shares. And BlackRock Fund Advisors has lifted its position by 49.24% or 2.28 million shares – to 6.91 million shares.
With over 1.03 million Regeneron Pharmaceuticals Inc. (REGN) shares trading Tuesday and a closing price of $592.68 on the day, the dollar volume was approximately $607.87 million. The shares have shown a negative weekly performance of -2.92% and its price on 09/01/20 lost nearly -4.40%. Currently, there are 109.60M common shares owned by the public and among those 101.60M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 27 analysts who have offered their price forecasts for REGN have a consensus price objective of $672.54. The analysts have set the share’s price value over the next 12 months at a high of $800.00 and a low of $550.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Regeneron Pharmaceuticals Inc. stock is 2.10 for the next 12 months. The average price target is 12.15% above its last price level and an upside to the estimated low will see the stock lose -7.76% over that period. But an upside of 25.92% will see the stock hit the forecast high price target while mean target price for the stock is $675.00.
Insiders at the company have transacted a total of 933 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 124 of these insider trades were purchases, accounting for 2,613,182 shares. Insider sales of the common stock occurred on 809 occasions, with total insider shares sold totaling 3,126,482 shares.
The top 3 mutual fund holders in Regeneron Pharmaceuticals Inc. are American Funds Growth Fund of Ame, Vanguard Total Stock Market Index, and Vanguard Health Care Fund. American Funds Growth Fund of Ame owns 3.38 million shares of the company’s stock, all valued at over $2.14 billion. The company sold 36500.0 shares recently to bring their total holdings to about 3.06% of the shares outstanding. Vanguard Total Stock Market Index sold 7679.0 shares to see its total holdings shrink to 2.72 million shares valued at over $1.72 billion and representing 2.46% of the shares outstanding. Vanguard Health Care Fund bought 0.77 million shares to bring its total holdings to over 2.56 million shares at a value of $1.62 billion. Vanguard Health Care Fund now owns shares totaling to 2.31% of the shares outstanding.
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) opened at $615.63, down -$4.3 from a prior closing price of $619.93. However, the script later closed the day at $592.68, down -4.40%. The company’s stock has a 5-day price change of -2.92% and -1.92% over the past three months. REGN shares are trading 57.85% year to date (YTD), with the 12-month market performance up to 107.87% higher. It has a 12-month low price of $271.37 and touched a high of $664.64 over the same period. Currently, 1.03 million shares have been traded, compared to an average intraday trading volume of 847.36K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.66%, -4.97%, and 18.66% respectively.
Institutional ownership of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) shares accounts for 93.30% of the company’s 109.60M shares outstanding. Mutual fund holders own 29.35%, while other institutional holders and individual stakeholders account for 55.44% and 23.57% respectively.
It has a market capitalization of $64.35B and a beta (3y monthly) value of 0.49. The stock’s trailing 12-month PE ratio is 22.95, while the earnings-per-share (ttm) stands at $25.83. The company has a PEG of 1.88 and a Quick Ratio of 1.80 with the debt-to-equity ratio at 0.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.83% over the week and 2.77% over the month.
Analysts forecast that Regeneron Pharmaceuticals Inc. (REGN) will achieve an EPS of $7.12 for the current quarter, $7.96 for the next quarter and $33.88 for 2021. The lowest estimate earnings-per-share for the quarter is $5.06 while analysts give the company a high EPS estimate of $10.43. Comparatively, EPS for the current quarter was $6.67 a year ago. Earnings per share for the fiscal year are expected to decrease by -10.80%, and 17.65% over the next financial year. EPS should shrink at an annualized rate of 12.18% over the next five years, compared to 44.00% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 27 brokerage firm advisors rate Regeneron Pharmaceuticals Inc. (REGN) as a “Moderate Buy” at a consensus score of 2.10. Specifically, 13 Wall Street analysts polled rate the stock as a buy, while 12 of the 27 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the REGN, a number of firms have released research notes about the stock. The Benchmark Company stated their Hold rating for the stock in a research note on August 20, 2020, with the firm’s price target at. SunTrust coverage for the Regeneron Pharmaceuticals Inc. (REGN) stock in a research note released on July 09, 2020 offered a Buy rating with a price target of $750. Wells Fargo was of a view on May 26, 2020 that the stock is Overweight, while Citigroup gave the stock Neutral rating on April 28, 2020, issuing a price target of $540- $575. The Benchmark Company on their part issued Buy rating on April 17, 2020.